Atrium Therapeutics (RNA)


Market Price (11/18/2026): $6.53 | Market Cap: $140.9 MilSector: Health Care | Industry: Biotechnology

Atrium Therapeutics (RNA)


Market Price (11/18/2026): $6.53
Market Cap: $140.9 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -210%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 87%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -56%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include mRNA Technology, Gene Editing & Therapy, Show more.

Weak multi-year price returns
2Y Excs Rtn is -80%, 3Y Excs Rtn is -124%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -103 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -265%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 46%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -205%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -214%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -93%

Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 16.07, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22%

Key risks
RNA key risks include [1] potential late-stage clinical trial setbacks for its key drug candidates, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -210%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 87%
2 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -56%
3 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include mRNA Technology, Gene Editing & Therapy, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -80%, 3Y Excs Rtn is -124%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -103 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -265%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 46%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -205%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -214%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -93%
9 Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 16.07, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22%
10 Key risks
RNA key risks include [1] potential late-stage clinical trial setbacks for its key drug candidates, Show more.

RNA in ETFs

Weight = RNA's share of each fund

VTI0.00%
IWM0.00%
IWO0.00%
VTWO0.00%
IWN0.00%
SCHA0.00%
SCHB0.00%
IWV0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 16: down 14.4% in one day (S&P 500 down 1.9%)
The stock declined without company news, as the broader market also fell, weighed down by chip stocks including Nvidia. Market analysis highlighted the Federal Reserve's chairman focusing on an AI revolution.

Down 56.0% from its Sep 3 high to Nov 16 (S&P 500 down 4.1%)
The stock experienced a significant decline over the period, largely without company-specific news, while the broader market also trended downwards. This run included substantial drops on September 8 and September 23, with a further decline on November 16.

Nov 13: up 0.1% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock was flat after third quarter 2026 financial results showed revenue growth, but significant net income and EPS losses. Positive clinical trial updates and nonclinical data likely offset these figures and a declining broader market.

Show more
Prices as of 11/17/2026

Nov 16: down 14.4% in one day (S&P 500 down 1.9%)
The stock declined without company news, as the broader market also fell, weighed down by chip stocks including Nvidia. Market analysis highlighted the Federal Reserve's chairman focusing on an AI revolution.

Down 56.0% from its Sep 3 high to Nov 16 (S&P 500 down 4.1%)
The stock experienced a significant decline over the period, largely without company-specific news, while the broader market also trended downwards. This run included substantial drops on September 8 and September 23, with a further decline on November 16.

Nov 13: up 0.1% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock was flat after third quarter 2026 financial results showed revenue growth, but significant net income and EPS losses. Positive clinical trial updates and nonclinical data likely offset these figures and a declining broader market.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -42.9% change in RNA stock from 7/31/2026 to 11/17/2026 was primarily driven by a 0.5% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611172026Change
Stock Price ($)11.356.48-42.9%
Change Contribution By: 
Total Revenues ($ Mil)�390.0%
P/S Multiple�2.80.0%
Shares Outstanding (Mil)17170.5%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
RNA-42.9% 
Market (SPY)-1.7%30.6%
Sector (XLV)14.4%42.5%

Fundamental Drivers

The -49.3% change in RNA stock from 4/30/2026 to 11/17/2026 was primarily driven by a -75.8% change in the company's P/S Multiple.
(LTM values as of)430202611172026Change
Stock Price ($)12.776.48-49.3%
Change Contribution By: 
Total Revenues ($ Mil)1939108.5%
P/S Multiple11.72.8-75.8%
Shares Outstanding (Mil)17170.4%
Cumulative Contribution-49.3%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
RNA-49.3% 
Market (SPY)2.4%32.4%
Sector (XLV)27.9%36.0%

Fundamental Drivers

null
null

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
RNA  
Market (SPY)8.5%29.6%
Sector (XLV)30.6%33.6%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
RNA  
Market (SPY)81.6%29.6%
Sector (XLV)56.4%33.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
RNA Return------56%-56%
Peers Return43%-20%3%78%-33%-20%13%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
RNA Win Rate-----30% 
Peers Win Rate46%50%46%58%75%32% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
RNA Max Drawdown------ 
Peers Max Drawdown-41%-46%-34%-26%-59%-52% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ASPE, ATYR, BBTX, CTY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

RNA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to VRTX, ASPE, ATYR, BBTX, CTY

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

RNA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to VRTX, ASPE, ATYR, BBTX, CTY

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Atrium Therapeutics (RNA)

```html

Trading under the symbol RNA, this biopharmaceutical company specializes in the development of innovative oligonucleotide-based therapies. Its core technology involves Antibody Oligonucleotide Conjugates (AOCs), which are precisely engineered to deliver therapeutic oligonucleotides to target tissues, aiming to treat a variety of serious diseases. This approach positions the company at the forefront of genetic medicine, focusing on developing treatments for conditions with significant unmet medical needs.

The company's product pipeline features several key candidates targeting rare muscle diseases. Its lead product candidate, AOC 1001, is being developed for the treatment of Myotonic Dystrophy Type 1, a rare monogenic muscle disorder. In earlier stages, the company is also advancing AOC 1044 for Duchenne Muscular Dystrophy and AOC 1020 for facioscapulohumeral muscular dystrophy, both of which are currently in preclinical development. Additionally, the company offers Lumizyme therapy, which is utilized for the treatment of Pompe disease.

The primary market served by this company consists of patients suffering from rare and severe genetic muscle diseases. By focusing on conditions such as Myotonic Dystrophy Type 1, Duchenne Muscular Dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease, the company targets specialized patient populations. Its mission is to leverage its AOC platform to develop targeted and potentially transformative treatments for these challenging disorders, addressing critical needs within the orphan drug and rare disease therapeutic areas.

```

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Atrium Therapeutics (symbol: RNA), which is described in the background as Avidity Biosciences, Inc., is a biopharmaceutical company that develops and commercializes therapies for serious diseases. As such, it sells its products primarily to individuals, specifically patients who suffer from these conditions, through the healthcare system.

The major categories of customers it serves are:

  • Patients with Myotonic Dystrophy Type 1
  • Patients with Duchenne Muscular Dystrophy
  • Patients with Facioscapulohumeral Muscular Dystrophy

AI Analysis | Feedback

null

AI Analysis | Feedback

Sarah Boyce, President and Chief Executive Officer

Sarah Boyce joined Avidity Biosciences as President and CEO in October 2019. She brings over 25 years of global leadership experience in the life sciences industry, having built global organizations and successfully launched innovative therapies such as Tegsedi®, Waylivra®, Soliris®, Gleevec®, and Tasigna®. Before joining Avidity, Ms. Boyce served as President and a board member of Akcea Therapeutics from April 2018 to September 2019, where she led the commercialization of the company's rare disease products. Her career includes executive roles at prominent pharmaceutical and biotech companies, including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology, and Roche. Ms. Boyce has also been instrumental in Avidity's growth, leading the company through a successful Series C funding round and an IPO. She currently serves on the boards of Ligand, Inc., OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. She holds a B.S. degree in microbiology from the University of Manchester, England.

Michael MacLean, Chief Financial and Chief Business Officer

Michael MacLean was appointed Chief Financial Officer of Avidity Biosciences in May 2020, and his role was expanded to include Chief Business Officer in April 2022. He possesses decades of industry experience, particularly in funding biotechnology companies, developing strategic plans, fostering partnerships for novel technologies, and advancing therapies in rare and orphan disease areas through commercialization. Prior to Avidity, Mr. MacLean served as Chief Financial Officer of Akcea Therapeutics, Inc., where he was responsible for building out its financial and global infrastructure. His previous experience also includes serving as Chief Financial Officer of PureTech Health, plc, and Chief Accounting Officer of Biogen Inc., where he oversaw worldwide finance operations. Mr. MacLean has been involved with companies that underwent acquisition; he was CFO of Akcea Therapeutics, which was eventually acquired, and he disposed of company equity in connection with Avidity Biosciences' merger with Novartis AG in February 2026.

Steve Hughes, MD, Chief Medical Officer

Dr. Steve Hughes joined Avidity Biosciences as Chief Medical Officer in February 2022. He brings over 20 years of experience in building and leading clinical development and medical affairs teams. Dr. Hughes has contributed to more than 50 clinical trials for over 25 drugs across various therapeutic areas, including cardiovascular, neurology, and several rare diseases. Before joining Avidity, he served as Chief Medical Officer at Arcturus Therapeutics, where he continues to act as a strategic clinical advisor. His prior positions include Chief Medical Officer at Organovo, Chief Clinical Development Officer at Ionis Pharmaceuticals, and roles at Biogen, CSL Behring, and Sanofi. Dr. Hughes is board certified in pharmaceutical medicine and earned his medical degree and an MBA from Imperial College, London.

AI Analysis | Feedback

Avidity Biosciences, Inc. (symbol: RNA) faces several key risks inherent to its operations as a clinical-stage biopharmaceutical company. These risks are primarily related to the uncertain nature of drug development, financial sustainability, and the competitive landscape. Here are the key risks to the business: 1. **Clinical Trial Success and Regulatory Approval:** As a biopharmaceutical company focused on developing novel oligonucleotide-based therapies, Avidity Biosciences' future success is heavily dependent on the successful outcomes of its ongoing and future clinical trials for its antibody oligonucleotide conjugate (AOC) product candidates. The company faces significant regulatory risks, particularly concerning novel therapies and accelerated approvals. Any setbacks, delays, or failures in these trials, including potential safety concerns, could significantly undermine the company's market position and investor confidence, as the biopharmaceutical industry is characterized by stringent regulatory requirements and unpredictable trial results. 2. **Financial Sustainability and Need for Additional Financing:** Avidity Biosciences operates with an accumulated deficit and ongoing net losses, which is typical for clinical-stage biotechnology firms due to the substantial research and development (R&D) costs involved in drug discovery and clinical trials. While the company has reported existing financial resources, it will require substantial additional financing to achieve its long-term goals and fund its development programs and commercialization efforts. Failure to secure this necessary capital could lead to delays or the termination of critical development programs. 3. **Competition and Market Access Challenges:** Avidity Biosciences operates in the competitive rare disease therapeutic space, facing competition from both established pharmaceutical companies and other emerging biotechnology firms. Successful commercialization of its product candidates, even if approved, could be challenged by market access hurdles typical in the rare disease sector, potentially impacting revenue generation and market penetration.

AI Analysis | Feedback

The primary clear emerging threat for Avidity Biosciences, Inc. (RNA) is the **rapid advancement and potential market dominance of competing novel therapeutic modalities from other biopharmaceutical companies.**

This includes:

  • The emergence of alternative targeted oligonucleotide delivery platforms or antibody-oligonucleotide conjugates (AOCs) from competitors that demonstrate superior efficacy, safety, or broader application for diseases such as myotonic dystrophy type 1, Duchenne Muscular Dystrophy, or facioscapulohumeral muscular dystrophy.
  • Significant breakthroughs in gene therapy or gene-editing technologies (e.g., CRISPR) that could offer more durable or curative treatments for these rare monogenic diseases, potentially rendering oligonucleotide-based approaches less competitive.

AI Analysis | Feedback

The addressable markets for Avidity Biosciences, Inc.'s main products are as follows:

  • AOC 1001 (Myotonic Dystrophy Type 1 - DM1): The global market for Myotonic Dystrophy Type 1 (DM1) is projected to grow from USD 1,550 million in 2024 to USD 3,204 million by 2032, exhibiting a compound annual growth rate (CAGR) of 9.5% over the forecast period. Another estimate places the global Myotonic Dystrophy Treatment Market size at US$ 874.39 Million in 2023, with a projection to reach approximately US$ 2,789.35 Million by 2033, growing at a CAGR of 12.3%. Myotonic dystrophy type 1 is estimated to affect approximately 80,000 individuals in the United States and Europe. In 2023, the United States accounted for nearly 54,068 diagnosed prevalent cases of Myotonic Dystrophy.

  • AOC 1044 (Duchenne Muscular Dystrophy - DMD): The global Duchenne Muscular Dystrophy (DMD) drugs market size was estimated at USD 3.47 billion in 2023 and is projected to reach USD 9.91 billion by 2030, with a CAGR of 16.8% from 2024 to 2030. Another report estimates the global Duchenne muscular dystrophy drugs market size at USD 4.79 billion in 2025, predicted to increase to approximately USD 19.46 billion by 2034, expanding at a CAGR of 16.85% from 2025 to 2034. There are approximately 15,000 patients with DMD in the U.S. Duchenne Muscular Dystrophy affects 1 in 3,500 to 5,000 boys born worldwide. AOC 1044 specifically targets DMD mutations amenable to exon 44 skipping, which accounts for around 6% of all DMD cases in the U.S.

  • AOC 1020 (Facioscapulohumeral Muscular Dystrophy - FSHD): The 7 major facioscapulohumeral muscular dystrophy markets (7MM includes the United States, EU4, and Japan) reached a value of USD 32.2 Million in 2024 and are expected to reach USD 61.4 Million by 2035, exhibiting a CAGR of 6.12% during 2025-2035. The U.S. alone represented about 45% of all FSHD cases across the 7MM in 2024. Overall, the United States accounts for the largest market share (around 80%) of the Facioscapulohumeral Muscular Dystrophy Market, when compared to EU4 and Japan. There are an estimated 45,000-87,000 patients with FSHD. In 2023, the total prevalent cases of FSHD in the 7MM were approximately 79,000. Currently, there are no available therapies that can slow, halt, or reverse the progression of muscle weakness in facioscapulohumeral muscular dystrophy.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Avidity Biosciences, Inc. (symbol: RNA) over the next 2-3 years:

  1. Advancement and Potential Commercialization of AOC 1001 (del-desiran) for Myotonic Dystrophy Type 1 (DM1): As Avidity Biosciences' lead product candidate, AOC 1001 (also known as del-desiran) is progressing through clinical development, with the global Phase 3 HARBOR trial initiated in mid-2024. Positive long-term data from earlier trials, demonstrating improvements in disease progression, support its potential. The company has received FDA Breakthrough Therapy Designation for AOC 1001 and is accelerating commercial preparations for a potential launch in rapid succession, which could contribute significantly to revenue within the next 2-3 years.
  2. Clinical Progress and Market Entry of AOC 1044 (del-zota) for Duchenne Muscular Dystrophy (DMD) amenable to Exon 44 Skipping (DMD44): AOC 1044 (del-zota) has demonstrated promising results in Phase 1/2 clinical trials, including significant increases in dystrophin production. The FDA has granted Fast Track designation for AOC 1044, and the company plans to submit a Biologics License Application (BLA) by year-end 2025, with an accelerated approval pathway confirmed. This timeline positions AOC 1044 for potential market entry and revenue generation within the next 2-3 years.
  3. Development and Future Launch of AOC 1020 (del-brax) for Facioscapulohumeral Muscular Dystrophy (FSHD): AOC 1020 (del-brax) has also received FDA Fast Track designation and shown positive initial data from its Phase 1/2 FORTITUDE trial, indicating reductions in disease-related gene expression and trends of functional improvement. Avidity Biosciences plans to accelerate the initiation of registrational cohorts and a global pivotal trial by mid-2025, with commercialization preparations underway, indicating a potential revenue driver in the near to medium term.
  4. Broader Pipeline Expansion and Platform Versatility: Avidity Biosciences is continuously advancing its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which is designed to deliver RNA therapeutics to target tissues. Beyond its lead programs, the company is developing additional AOCs for various Duchenne muscular dystrophy mutations and expanding its pipeline into other rare neuromuscular diseases. The ongoing discovery and development of new candidates leveraging the AOC platform represent a sustained driver of future growth through new product launches or partnership milestones.
  5. Strategic Collaborations and Milestone Payments: As a clinical-stage biopharmaceutical company, Avidity Biosciences generates revenue through collaborations and achieving developmental milestones with larger pharmaceutical partners. For instance, the company received a $10.0 million clinical development milestone payment from Eli Lilly and Company in the third quarter of 2025. Continued progress of its clinical programs is expected to trigger further milestone payments and potential future licensing agreements, contributing to its revenue streams.

AI Analysis | Feedback

Share Issuance

  • Avidity Biosciences closed an underwritten public offering in September 2025, selling 17,250,000 shares of its common stock at $40.00 per share, which generated gross proceeds of $690.0 million.
  • In February 2024, the company agreed to sell 15,224,773 shares of common stock and pre-funded warrants for 9,030,851 shares in a private placement, resulting in approximately $400 million in gross proceeds.

Inbound Investments

  • Novartis AG completed the acquisition of Avidity Biosciences on February 27, 2026, in an all-cash deal valued at approximately $12 billion, with Avidity shareholders receiving $72.00 per share.
  • During the third quarter of 2025, Readystate Asset Management LP acquired a new stake of 15,505 shares of Avidity Biosciences, valued at about $676,000.
  • JPMorgan Chase & Co. significantly increased its stake in Avidity Biosciences by 55% in Q3 2025, holding 899,557 shares worth approximately $39.2 million.

Outbound Investments

  • Prior to its acquisition by Novartis, Avidity Biosciences spun off its early-stage precision cardiology assets into a new, independent public company named Atrium Therapeutics, Inc. (now trading under symbol RNA) in February 2026.
  • As part of the spin-off, Avidity distributed one share of Atrium Therapeutics common stock for every ten shares of Avidity common stock held by its shareholders.
  • Atrium Therapeutics, Inc. launched with approximately $270 million in cash to advance its pipeline.

Capital Expenditures

  • Avidity Biosciences' capital expenditures were $3.74 million in 2021, $2.82 million in 2022, $4.23 million in 2023, and $7.07 million in 2024.
  • Expected capital expenditures for 2025 are projected to be $13 million.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

RNAVRTXASPEATYRBBTXCTYMedian
NameAtrium T.Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
Mkt Price6.53530.0512.244.8116.2817.6114.26
Mkt Cap0.1134.4----67.2
Rev LTM3912,952-0--39
Op Inc LTM-1034,288--56---56
FCF LTM-833,202--44---44
FCF 3Y Avg-1,729--58--836
CFO LTM-803,695--44---44
CFO 3Y Avg-2,190--58--1,066

Growth & Margins

RNAVRTXASPEATYRBBTXCTYMedian
NameAtrium T.Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
Rev Chg LTM87.2%10.5%--100.0%--10.5%
Rev Chg 3Y Avg-10.3%--72.3%---31.0%
Rev Chg Q24.2%11.8%--100.0%--11.8%
QoQ Delta Rev Chg LTM8.3%2.9%--100.0%--2.9%
Op Inc Chg LTM-283.9%4,760.7%-28.9%--28.9%
Op Inc Chg 3Y Avg-1,548.2%--10.6%--768.8%
Op Mgn LTM-264.8%33.1%-----115.9%
Op Mgn 3Y Avg-22.4%----22.4%
QoQ Delta Op Mgn LTM4.1%-4.8%-----0.4%
CFO/Rev LTM-205.3%28.5%-----88.4%
CFO/Rev 3Y Avg-17.4%----17.4%
FCF/Rev LTM-214.1%24.7%-----94.7%
FCF/Rev 3Y Avg-13.5%----13.5%

Valuation

RNAVRTXASPEATYRBBTXCTYMedian
NameAtrium T.Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
Mkt Cap0.1134.4----67.2
P/S2.910.4----6.6
P/Op Inc-1.131.3----15.1
P/EBIT-1.129.5----14.2
P/E-1.133.8----16.3
P/CFO-1.436.4----17.5
Total Yield-88.2%2.9%-----42.6%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-1.5%----1.5%
D/E0.00.0----0.0
Net D/E-2.10.0-----1.0

Returns

RNAVRTXASPEATYRBBTXCTYMedian
NameAtrium T.Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
1M Rtn-14.9%6.1%-17.8%-30.9%8.6%-21.4%-16.3%
3M Rtn-49.1%0.4%-17.8%-76.1%8.6%-21.4%-19.6%
6M Rtn-49.6%22.0%-17.8%-75.1%8.6%-21.4%-19.6%
12M Rtn-55.7%22.1%-17.8%-82.3%8.6%-21.4%-19.6%
3Y Rtn-55.7%51.2%-17.8%-89.5%8.6%-21.4%-19.6%
1M Excs Rtn-10.6%9.1%-14.2%-26.5%12.2%-14.4%-12.4%
3M Excs Rtn-48.6%-0.2%-13.9%-73.8%12.4%-17.6%-15.8%
6M Excs Rtn-50.4%21.2%-18.7%-75.9%7.8%-22.2%-20.5%
12M Excs Rtn-65.9%11.2%-28.1%-93.8%-1.5%-31.6%-29.9%
3Y Excs Rtn-124.2%-25.6%-87.1%-154.8%-59.1%-89.8%-88.5%

Financials

Price Behavior

Price Behavior
Market Price$6.48 
Market Cap ($ Bil)0.1 
First Trading Date06/12/2020 
Distance from 52W High-60.8% 
   50 Days200 Days
DMA Price$8.40 
DMA Trenddown 
Distance from DMA-22.8% 
 3M1YR
Volatility65.9%53.7%
Downside Capture376.93 
Upside Capture57.39 
Correlation (S&P 500)32.1% 
RNA Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.151.781.551.230.140.11
Up Beta-3.610.790.261.69-0.020.05
Down Beta-1.59-1.62-0.190.43-0.08-0.03
Up Capture111%153%166%69%46%4%
Bmk +ve Days12182862130427
Stock +ve Days122133578080
Down Capture98%392%293%182%126%74%
Bmk -ve Days10253664121325
Stock -ve Days102130668686

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with RNA
RNA-56.2%53.7%-1.92-
Sector ETF (XLV)24.2%16.9%1.1033.6%
Equity (SPY)10.2%13.8%0.4529.6%
Gold (GLD)-6.3%28.8%-0.2323.7%
Commodities (DBC)31.6%21.3%1.18-12.8%
Real Estate (VNQ)10.0%14.2%0.4219.9%
Bitcoin (BTCUSD)-31.4%43.7%-0.7529.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with RNA
RNA-15.2%53.7%-1.92-
Sector ETF (XLV)8.6%15.4%0.3633.6%
Equity (SPY)10.9%17.3%0.4629.6%
Gold (GLD)15.5%19.2%0.6523.7%
Commodities (DBC)7.1%19.6%0.25-12.8%
Real Estate (VNQ)0.9%19.0%-0.0619.9%
Bitcoin (BTCUSD)-0.6%51.4%0.1729.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with RNA
RNA-7.9%53.7%-1.92-
Sector ETF (XLV)12.4%16.8%0.6133.6%
Equity (SPY)14.9%18.0%0.7029.6%
Gold (GLD)11.2%16.6%0.5523.7%
Commodities (DBC)7.4%18.2%0.32-12.8%
Real Estate (VNQ)5.8%20.7%0.2419.9%
Bitcoin (BTCUSD)57.2%66.3%0.9729.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity3.7 Mil
Short Interest: % Change Since 101520260.6%
Average Daily Volume0.2 Mil
Days-to-Cover Short Interest16.1 days
Basic Shares Quantity17.0 Mil
Short % of Basic Shares22.0%

Earnings Returns History

Updated 11/17/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/20260.1%  
8/13/20264.1%9.3%-17.2%
5/14/2026-0.3%-1.7%-3.9%
SUMMARY STATS   
# Positive210
# Negative112
Median Positive2.1%9.3% 
Median Negative-0.3%-1.7%-10.6%
Max Positive4.1%9.3% 
Max Negative-0.3%-1.7%-17.2%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/20260.1%  
8/13/20264.1%9.3%-17.2%
5/14/2026-0.3%-1.7%-3.9%
SUMMARY STATS   
# Positive210
# Negative112
Median Positive2.1%9.3% 
Median Negative-0.3%-1.7%-10.6%
Max Positive4.1%9.3% 
Max Negative-0.3%-1.7%-17.2%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/13/202610-Q
03/31/202605/14/202610-Q
12/31/202502/17/202610-12B/A
09/30/202501/30/202610-12B/A
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/13/202610-Q
03/31/202605/14/202610-Q
12/31/202502/17/202610-12B/A
09/30/202501/30/202610-12B/A

Insider Activity

Updated 9/22/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Hughes, Steven GeorgeChief Medical OfficerDirectSell123202672.454,895354,6432,289,348Form
2Boyce, SarahPresident and CEODirectSell123202672.4514,3871,042,33819,489,557Form
3Flanagan, W. MichaelChief Scientific OfficerDirectSell123202672.456,534473,3886,164,988Form
4MacLean, Michael FChief Financial OfficerDirectSell123202672.454,542329,0684,295,560Form
5Levin, Arthur A DirectSell123202672.451,758127,3671,199,917Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Hughes, Steven GeorgeChief Medical OfficerDirectSell123202672.454,895354,6432,289,348Form
2Boyce, SarahPresident and CEODirectSell123202672.4514,3871,042,33819,489,557Form
3Flanagan, W. MichaelChief Scientific OfficerDirectSell123202672.456,534473,3886,164,988Form
4MacLean, Michael FChief Financial OfficerDirectSell123202672.454,542329,0684,295,560Form
5Levin, Arthur A DirectSell123202672.451,758127,3671,199,917Form
6McCarthy, TeresaChief Human Resources OfficerDirectSell123202672.452,929212,2068,254,808Form
7Hughes, Steven GeorgeChief Medical OfficerDirectSell1024202547.542,209105,0151,847,714Form
8McCarthy, TeresaChief Human Resources OfficerDirectSell1017202550.1520,0001,003,0584,871,351Form
9Mosbrooker, EricChief Commercial OfficerDirectSell1007202545.386,562297,7712,495,796Form
10Hughes, Steven GeorgeChief Medical OfficerDirectSell923202540.582,20889,6011,577,223Form
11McCarthy, TeresaChief Human Resources OfficerDirectSell917202541.4115,000621,1424,022,105Form
12Hughes, Steven GeorgeChief Medical OfficerDirectSell917202545.411,54270,0221,764,950Form
13Flanagan, W. MichaelChief Scientific OfficerDirectSell912202538.9420,000778,7023,122,400Form
14Wilson, Troy Edward DirectSell909202550.0029,5001,475,0002,721,250Form
15Boyce, SarahPresident and CEODirectSell905202549.9550,0002,497,43515,277,859Form
16Mosbrooker, EricChief Commercial OfficerDirectSell905202547.076,563308,9362,588,976Form
17Gallagher, Kathleen PChief Program OfficerDirectSell902202547.421888,9152,380,674Form

Investor Activity (13F)

Updated Nov 18, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sessa Capital IM, L.P.$7.4 Mil0.1%31New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sessa Capital IM, L.P.$7.4 Mil0.1%31New13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sessa Capital IM, L.P.$7.4 Mil0.1%31New13F
Core Cache Last Updated: 11/17/2026